Retinoblastoma in Asia: Clinical Presentation and Treatment Outcomes in 2112 Patients from 33 Countries
To describe the clinical presentation and treatment outcomes of children who received a diagnosis of retinoblastoma in 2017 throughout Asia. Multinational, prospective study including treatment-naïve patients in Asia who received a diagnosis of retinoblastoma in 2017 and were followed up thereafter....
Gespeichert in:
| Veröffentlicht in: | Ophthalmology (Rochester, Minn.) Minn.), 2024-04, Vol.131 (4), p.468-477 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 477 |
|---|---|
| container_issue | 4 |
| container_start_page | 468 |
| container_title | Ophthalmology (Rochester, Minn.) |
| container_volume | 131 |
| creator | Kaliki, Swathi Vempuluru, Vijitha S Mohamed, Ashik Al-Jadiry, Mazin Faisal Bowman, Richard Chawla, Bhavna Hamid, Syed Ahmer Ji, Xunda Kapelushnik, Noa Kebudi, Rejin Sthapit, Purnima Rajkarnikar Rojanaporn, Duangnate Sitorus, Rita S Yousef, Yacoub Abdallah Fabian, Ido Didi |
| description | To describe the clinical presentation and treatment outcomes of children who received a diagnosis of retinoblastoma in 2017 throughout Asia.
Multinational, prospective study including treatment-naïve patients in Asia who received a diagnosis of retinoblastoma in 2017 and were followed up thereafter.
A total of 2112 patients (2797 eyes) from 96 retinoblastoma treatment centers in 33 Asian countries.
Chemotherapy, radiotherapy, enucleation, and orbital exenteration.
Enucleation and death.
Within the cohort, 1021 patients (48%) were from South Asia (SA), 503 patients (24%) were from East Asia (EA), 310 patients (15%) were from Southeast Asia (SEA), 218 patients (10%) were from West Asia (WA), and 60 patients (3%) were from Central Asia (CA). Mean age at presentation was 27 months (median, 23 months; range, < 1-261 months). The cohort included 1195 male patients (57%) and 917 female patients (43%). The most common presenting symptoms were leukocoria (72%) and strabismus (13%). Using the American Joint Committee on Cancer Staging Manual, Eighth Edition, classification, tumors were staged as cT1 (n = 441 [16%]), cT2 (n = 951 [34%]), cT3 (n = 1136 [41%]), cT4 (n = 267 [10%]), N1 (n = 48 [2%]), and M1 (n = 129 [6%]) at presentation. Retinoblastoma was treated with intravenous chemotherapy in 1450 eyes (52%) and 857 eyes (31%) underwent primary enucleation. Three-year Kaplan-Meier estimates for enucleation and death were 33% and 13% for CA, 18% and 4% for EA, 27% and 15% for SA, 32% and 22% for SEA, and 20% and 11% for WA (P < 0.0001 and P < 0.0001), respectively.
At the conclusion of this study, significant heterogeneity was found in treatment outcomes of retinoblastoma among the regions of Asia. East Asia displayed better outcomes with higher rates of globe and life salvage, whereas Southeast Asia showed poorer outcomes compared with the rest of Asia.
The author(s) have no proprietary or commercial interest in any materials discussed in this article. |
| doi_str_mv | 10.1016/j.ophtha.2023.10.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2878020496</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2878020496</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-d0c1d61338aa306b132e92ad77ad70bc2cf78b7bfced2d3a88d2707e71ee0a953</originalsourceid><addsrcrecordid>eNo1kE1Lw0AQhhdBbK3-A5E9ekncjySbeCvBqlBokXoOk-zEbkl2Y3Zz8N8bsR6GF573mTkMIXecxZzx7PEUu-EYjhALJuSMYsbTC7LkaVJEieJyQa69PzHGskwmV2QhVS6LNC2W5PMdg7Gu7sAH1wM1lq69gSdadsaaBjq6H9GjDRCMsxSspocRIfQzorspNK5H_7slOBd0P1tz4Wk7up5KSUs32TAa9DfksoXO4-05V-Rj83woX6Pt7uWtXG-jgYssRJo1XGdcyhxAsqzmUmAhQCs1D6sb0bQqr1XdNqiFlpDnWiimUHFEBkUqV-Th7-4wuq8Jfah64xvsOrDoJl-JXOVMsKTIZvX-rE51j7oaRtPD-F39P0f-AKfvZuA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2878020496</pqid></control><display><type>article</type><title>Retinoblastoma in Asia: Clinical Presentation and Treatment Outcomes in 2112 Patients from 33 Countries</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kaliki, Swathi ; Vempuluru, Vijitha S ; Mohamed, Ashik ; Al-Jadiry, Mazin Faisal ; Bowman, Richard ; Chawla, Bhavna ; Hamid, Syed Ahmer ; Ji, Xunda ; Kapelushnik, Noa ; Kebudi, Rejin ; Sthapit, Purnima Rajkarnikar ; Rojanaporn, Duangnate ; Sitorus, Rita S ; Yousef, Yacoub Abdallah ; Fabian, Ido Didi</creator><creatorcontrib>Kaliki, Swathi ; Vempuluru, Vijitha S ; Mohamed, Ashik ; Al-Jadiry, Mazin Faisal ; Bowman, Richard ; Chawla, Bhavna ; Hamid, Syed Ahmer ; Ji, Xunda ; Kapelushnik, Noa ; Kebudi, Rejin ; Sthapit, Purnima Rajkarnikar ; Rojanaporn, Duangnate ; Sitorus, Rita S ; Yousef, Yacoub Abdallah ; Fabian, Ido Didi ; Global Retinoblastoma Study Group</creatorcontrib><description>To describe the clinical presentation and treatment outcomes of children who received a diagnosis of retinoblastoma in 2017 throughout Asia.
Multinational, prospective study including treatment-naïve patients in Asia who received a diagnosis of retinoblastoma in 2017 and were followed up thereafter.
A total of 2112 patients (2797 eyes) from 96 retinoblastoma treatment centers in 33 Asian countries.
Chemotherapy, radiotherapy, enucleation, and orbital exenteration.
Enucleation and death.
Within the cohort, 1021 patients (48%) were from South Asia (SA), 503 patients (24%) were from East Asia (EA), 310 patients (15%) were from Southeast Asia (SEA), 218 patients (10%) were from West Asia (WA), and 60 patients (3%) were from Central Asia (CA). Mean age at presentation was 27 months (median, 23 months; range, < 1-261 months). The cohort included 1195 male patients (57%) and 917 female patients (43%). The most common presenting symptoms were leukocoria (72%) and strabismus (13%). Using the American Joint Committee on Cancer Staging Manual, Eighth Edition, classification, tumors were staged as cT1 (n = 441 [16%]), cT2 (n = 951 [34%]), cT3 (n = 1136 [41%]), cT4 (n = 267 [10%]), N1 (n = 48 [2%]), and M1 (n = 129 [6%]) at presentation. Retinoblastoma was treated with intravenous chemotherapy in 1450 eyes (52%) and 857 eyes (31%) underwent primary enucleation. Three-year Kaplan-Meier estimates for enucleation and death were 33% and 13% for CA, 18% and 4% for EA, 27% and 15% for SA, 32% and 22% for SEA, and 20% and 11% for WA (P < 0.0001 and P < 0.0001), respectively.
At the conclusion of this study, significant heterogeneity was found in treatment outcomes of retinoblastoma among the regions of Asia. East Asia displayed better outcomes with higher rates of globe and life salvage, whereas Southeast Asia showed poorer outcomes compared with the rest of Asia.
The author(s) have no proprietary or commercial interest in any materials discussed in this article.</description><identifier>EISSN: 1549-4713</identifier><identifier>DOI: 10.1016/j.ophtha.2023.10.015</identifier><identifier>PMID: 37839559</identifier><language>eng</language><publisher>United States</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Asia - epidemiology ; Child ; Child, Preschool ; Eye Enucleation ; Female ; Humans ; Infant ; Male ; Prospective Studies ; Retinal Neoplasms - diagnosis ; Retinal Neoplasms - epidemiology ; Retinal Neoplasms - therapy ; Retinoblastoma - diagnosis ; Retinoblastoma - epidemiology ; Retinoblastoma - therapy ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Ophthalmology (Rochester, Minn.), 2024-04, Vol.131 (4), p.468-477</ispartof><rights>Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37839559$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaliki, Swathi</creatorcontrib><creatorcontrib>Vempuluru, Vijitha S</creatorcontrib><creatorcontrib>Mohamed, Ashik</creatorcontrib><creatorcontrib>Al-Jadiry, Mazin Faisal</creatorcontrib><creatorcontrib>Bowman, Richard</creatorcontrib><creatorcontrib>Chawla, Bhavna</creatorcontrib><creatorcontrib>Hamid, Syed Ahmer</creatorcontrib><creatorcontrib>Ji, Xunda</creatorcontrib><creatorcontrib>Kapelushnik, Noa</creatorcontrib><creatorcontrib>Kebudi, Rejin</creatorcontrib><creatorcontrib>Sthapit, Purnima Rajkarnikar</creatorcontrib><creatorcontrib>Rojanaporn, Duangnate</creatorcontrib><creatorcontrib>Sitorus, Rita S</creatorcontrib><creatorcontrib>Yousef, Yacoub Abdallah</creatorcontrib><creatorcontrib>Fabian, Ido Didi</creatorcontrib><creatorcontrib>Global Retinoblastoma Study Group</creatorcontrib><title>Retinoblastoma in Asia: Clinical Presentation and Treatment Outcomes in 2112 Patients from 33 Countries</title><title>Ophthalmology (Rochester, Minn.)</title><addtitle>Ophthalmology</addtitle><description>To describe the clinical presentation and treatment outcomes of children who received a diagnosis of retinoblastoma in 2017 throughout Asia.
Multinational, prospective study including treatment-naïve patients in Asia who received a diagnosis of retinoblastoma in 2017 and were followed up thereafter.
A total of 2112 patients (2797 eyes) from 96 retinoblastoma treatment centers in 33 Asian countries.
Chemotherapy, radiotherapy, enucleation, and orbital exenteration.
Enucleation and death.
Within the cohort, 1021 patients (48%) were from South Asia (SA), 503 patients (24%) were from East Asia (EA), 310 patients (15%) were from Southeast Asia (SEA), 218 patients (10%) were from West Asia (WA), and 60 patients (3%) were from Central Asia (CA). Mean age at presentation was 27 months (median, 23 months; range, < 1-261 months). The cohort included 1195 male patients (57%) and 917 female patients (43%). The most common presenting symptoms were leukocoria (72%) and strabismus (13%). Using the American Joint Committee on Cancer Staging Manual, Eighth Edition, classification, tumors were staged as cT1 (n = 441 [16%]), cT2 (n = 951 [34%]), cT3 (n = 1136 [41%]), cT4 (n = 267 [10%]), N1 (n = 48 [2%]), and M1 (n = 129 [6%]) at presentation. Retinoblastoma was treated with intravenous chemotherapy in 1450 eyes (52%) and 857 eyes (31%) underwent primary enucleation. Three-year Kaplan-Meier estimates for enucleation and death were 33% and 13% for CA, 18% and 4% for EA, 27% and 15% for SA, 32% and 22% for SEA, and 20% and 11% for WA (P < 0.0001 and P < 0.0001), respectively.
At the conclusion of this study, significant heterogeneity was found in treatment outcomes of retinoblastoma among the regions of Asia. East Asia displayed better outcomes with higher rates of globe and life salvage, whereas Southeast Asia showed poorer outcomes compared with the rest of Asia.
The author(s) have no proprietary or commercial interest in any materials discussed in this article.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Asia - epidemiology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Eye Enucleation</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Prospective Studies</subject><subject>Retinal Neoplasms - diagnosis</subject><subject>Retinal Neoplasms - epidemiology</subject><subject>Retinal Neoplasms - therapy</subject><subject>Retinoblastoma - diagnosis</subject><subject>Retinoblastoma - epidemiology</subject><subject>Retinoblastoma - therapy</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>1549-4713</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1Lw0AQhhdBbK3-A5E9ekncjySbeCvBqlBokXoOk-zEbkl2Y3Zz8N8bsR6GF573mTkMIXecxZzx7PEUu-EYjhALJuSMYsbTC7LkaVJEieJyQa69PzHGskwmV2QhVS6LNC2W5PMdg7Gu7sAH1wM1lq69gSdadsaaBjq6H9GjDRCMsxSspocRIfQzorspNK5H_7slOBd0P1tz4Wk7up5KSUs32TAa9DfksoXO4-05V-Rj83woX6Pt7uWtXG-jgYssRJo1XGdcyhxAsqzmUmAhQCs1D6sb0bQqr1XdNqiFlpDnWiimUHFEBkUqV-Th7-4wuq8Jfah64xvsOrDoJl-JXOVMsKTIZvX-rE51j7oaRtPD-F39P0f-AKfvZuA</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Kaliki, Swathi</creator><creator>Vempuluru, Vijitha S</creator><creator>Mohamed, Ashik</creator><creator>Al-Jadiry, Mazin Faisal</creator><creator>Bowman, Richard</creator><creator>Chawla, Bhavna</creator><creator>Hamid, Syed Ahmer</creator><creator>Ji, Xunda</creator><creator>Kapelushnik, Noa</creator><creator>Kebudi, Rejin</creator><creator>Sthapit, Purnima Rajkarnikar</creator><creator>Rojanaporn, Duangnate</creator><creator>Sitorus, Rita S</creator><creator>Yousef, Yacoub Abdallah</creator><creator>Fabian, Ido Didi</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>202404</creationdate><title>Retinoblastoma in Asia: Clinical Presentation and Treatment Outcomes in 2112 Patients from 33 Countries</title><author>Kaliki, Swathi ; Vempuluru, Vijitha S ; Mohamed, Ashik ; Al-Jadiry, Mazin Faisal ; Bowman, Richard ; Chawla, Bhavna ; Hamid, Syed Ahmer ; Ji, Xunda ; Kapelushnik, Noa ; Kebudi, Rejin ; Sthapit, Purnima Rajkarnikar ; Rojanaporn, Duangnate ; Sitorus, Rita S ; Yousef, Yacoub Abdallah ; Fabian, Ido Didi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-d0c1d61338aa306b132e92ad77ad70bc2cf78b7bfced2d3a88d2707e71ee0a953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Asia - epidemiology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Eye Enucleation</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Prospective Studies</topic><topic>Retinal Neoplasms - diagnosis</topic><topic>Retinal Neoplasms - epidemiology</topic><topic>Retinal Neoplasms - therapy</topic><topic>Retinoblastoma - diagnosis</topic><topic>Retinoblastoma - epidemiology</topic><topic>Retinoblastoma - therapy</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaliki, Swathi</creatorcontrib><creatorcontrib>Vempuluru, Vijitha S</creatorcontrib><creatorcontrib>Mohamed, Ashik</creatorcontrib><creatorcontrib>Al-Jadiry, Mazin Faisal</creatorcontrib><creatorcontrib>Bowman, Richard</creatorcontrib><creatorcontrib>Chawla, Bhavna</creatorcontrib><creatorcontrib>Hamid, Syed Ahmer</creatorcontrib><creatorcontrib>Ji, Xunda</creatorcontrib><creatorcontrib>Kapelushnik, Noa</creatorcontrib><creatorcontrib>Kebudi, Rejin</creatorcontrib><creatorcontrib>Sthapit, Purnima Rajkarnikar</creatorcontrib><creatorcontrib>Rojanaporn, Duangnate</creatorcontrib><creatorcontrib>Sitorus, Rita S</creatorcontrib><creatorcontrib>Yousef, Yacoub Abdallah</creatorcontrib><creatorcontrib>Fabian, Ido Didi</creatorcontrib><creatorcontrib>Global Retinoblastoma Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmology (Rochester, Minn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaliki, Swathi</au><au>Vempuluru, Vijitha S</au><au>Mohamed, Ashik</au><au>Al-Jadiry, Mazin Faisal</au><au>Bowman, Richard</au><au>Chawla, Bhavna</au><au>Hamid, Syed Ahmer</au><au>Ji, Xunda</au><au>Kapelushnik, Noa</au><au>Kebudi, Rejin</au><au>Sthapit, Purnima Rajkarnikar</au><au>Rojanaporn, Duangnate</au><au>Sitorus, Rita S</au><au>Yousef, Yacoub Abdallah</au><au>Fabian, Ido Didi</au><aucorp>Global Retinoblastoma Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retinoblastoma in Asia: Clinical Presentation and Treatment Outcomes in 2112 Patients from 33 Countries</atitle><jtitle>Ophthalmology (Rochester, Minn.)</jtitle><addtitle>Ophthalmology</addtitle><date>2024-04</date><risdate>2024</risdate><volume>131</volume><issue>4</issue><spage>468</spage><epage>477</epage><pages>468-477</pages><eissn>1549-4713</eissn><abstract>To describe the clinical presentation and treatment outcomes of children who received a diagnosis of retinoblastoma in 2017 throughout Asia.
Multinational, prospective study including treatment-naïve patients in Asia who received a diagnosis of retinoblastoma in 2017 and were followed up thereafter.
A total of 2112 patients (2797 eyes) from 96 retinoblastoma treatment centers in 33 Asian countries.
Chemotherapy, radiotherapy, enucleation, and orbital exenteration.
Enucleation and death.
Within the cohort, 1021 patients (48%) were from South Asia (SA), 503 patients (24%) were from East Asia (EA), 310 patients (15%) were from Southeast Asia (SEA), 218 patients (10%) were from West Asia (WA), and 60 patients (3%) were from Central Asia (CA). Mean age at presentation was 27 months (median, 23 months; range, < 1-261 months). The cohort included 1195 male patients (57%) and 917 female patients (43%). The most common presenting symptoms were leukocoria (72%) and strabismus (13%). Using the American Joint Committee on Cancer Staging Manual, Eighth Edition, classification, tumors were staged as cT1 (n = 441 [16%]), cT2 (n = 951 [34%]), cT3 (n = 1136 [41%]), cT4 (n = 267 [10%]), N1 (n = 48 [2%]), and M1 (n = 129 [6%]) at presentation. Retinoblastoma was treated with intravenous chemotherapy in 1450 eyes (52%) and 857 eyes (31%) underwent primary enucleation. Three-year Kaplan-Meier estimates for enucleation and death were 33% and 13% for CA, 18% and 4% for EA, 27% and 15% for SA, 32% and 22% for SEA, and 20% and 11% for WA (P < 0.0001 and P < 0.0001), respectively.
At the conclusion of this study, significant heterogeneity was found in treatment outcomes of retinoblastoma among the regions of Asia. East Asia displayed better outcomes with higher rates of globe and life salvage, whereas Southeast Asia showed poorer outcomes compared with the rest of Asia.
The author(s) have no proprietary or commercial interest in any materials discussed in this article.</abstract><cop>United States</cop><pmid>37839559</pmid><doi>10.1016/j.ophtha.2023.10.015</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1549-4713 |
| ispartof | Ophthalmology (Rochester, Minn.), 2024-04, Vol.131 (4), p.468-477 |
| issn | 1549-4713 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2878020496 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asia - epidemiology Child Child, Preschool Eye Enucleation Female Humans Infant Male Prospective Studies Retinal Neoplasms - diagnosis Retinal Neoplasms - epidemiology Retinal Neoplasms - therapy Retinoblastoma - diagnosis Retinoblastoma - epidemiology Retinoblastoma - therapy Retrospective Studies Treatment Outcome |
| title | Retinoblastoma in Asia: Clinical Presentation and Treatment Outcomes in 2112 Patients from 33 Countries |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T18%3A29%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retinoblastoma%20in%20Asia:%20Clinical%20Presentation%20and%20Treatment%20Outcomes%20in%202112%20Patients%20from%2033%20Countries&rft.jtitle=Ophthalmology%20(Rochester,%20Minn.)&rft.au=Kaliki,%20Swathi&rft.aucorp=Global%20Retinoblastoma%20Study%20Group&rft.date=2024-04&rft.volume=131&rft.issue=4&rft.spage=468&rft.epage=477&rft.pages=468-477&rft.eissn=1549-4713&rft_id=info:doi/10.1016/j.ophtha.2023.10.015&rft_dat=%3Cproquest_pubme%3E2878020496%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2878020496&rft_id=info:pmid/37839559&rfr_iscdi=true |